Abdominal pain: do not forget Thorotrast!

Eric Weber, Fatima Laarbaui, Luc Michel, Julian Donckier

Summary
The use of Thorotrast (25% thorium dioxide), a radiologic contrast agent used up until the mid-1950s, was associated with a wide range of malignancies, mainly of hepatic origin. We report a case of Thorotrast-induced hepatocarcinoma in an 82-year-old woman.

Keywords: Thorotrast, hepatocarcinoma, carcinogen

Thorotrast (25% thorium dioxide), a radiologic contrast agent used between 1928 and 1955, was abandoned following a report by MacMahon of hepatic angiosarcoma attributed to Thorotrast exposure. Thorium dioxide has radioactive properties due to the emission of alpha-, beta- and gamma-rays with a biological half-life of 400 years. Its use has been associated with the development of a wide range of malignancies, mainly of hepatic origin. We here report an additional case of Thorotrast-induced hepatocarcinoma.

Thorotrast

Thorium
- a radioactive compound (90% α-rays, 9% β-rays, 1% γ-rays)
- biological half-life: 400 years
- physical half-life: 14 million years

Indications
- cerebral arteriography and ventriculography
- hepatopancreaticography
- instillation for visualising body cavities
- pyelography

Composition
- 25% colloidal solution of thorium dioxide (ThO₂)
- 20% dextran
- 0.15%, methyl hydroxybenzoate
  (= 200 mg of ²³²thorium/ml)

Thorotrast-associated lesions
- hepatic angiosarcoma
- cholangiocarcinoma
- hepatoma
- urotheloma
- blood dyscrasias (erythroleukemia, myelogenous leukemia)
- lung cancers
- ‘Thorotrastomas’ at injection site
- CNS tumour, etc

Case report
A 82-year-old woman was admitted with sudden right-sided abdominal pain. An aortic valvular replacement had been performed eight years earlier and the patient had experienced three interventions for inguinal hernia correction and ovariectomy in the 1940s. Physical examination revealed abdominal tenderness in the right upper quadrant. The erythrocyte sedimentation rate was 44 mm/h, fibrinogen 670 mg/dl, bilirubin 2.9 mg/dl, serum aspartate aminotransferase 75 UI/l, serum alanine aminotransferase 29 UI/l, γ-glutamyl transferase 54 UI/l, lactic dehydrogenase 678 UI/l, and alkaline phosphatase 203 UI/l. Serology for viral hepatitis indicated immunity for virus B but not for virus A and C. Anti-smooth muscle and anti-mitochondria antibodies were absent. Carcinoembryogenic antigen was normal and α-fetoprotein slightly elevated to 7.1 ng/ml. Ferritin was normal. A plain film of the abdomen demonstrated fine, irregular metallic densities distributed throughout the liver, spleen and parapancratic lymph nodes (figure 1). This pattern was pathognomonic for Thorotrast deposits. A computed tomographic (CT) scan without contrast injection demonstrated hyperdensities in the liver, spleen and lymph nodes of the hilar region and disclosed a tumoral lesion in segment IV (figure 2), which was confirmed by magnetic resonance imaging (MRI). The diagnosis of hepatocarcinoma induced by Thorotrast exposure was proved by a liver biopsy showing black pigmented deposits in the vicinity of the tumor. Surprisingly, the patient did not remember such an injection. Given the patient’s age, cardiovascular state and the poor prognosis, therapeutic abstention was decided. The initial symptoms resolved spontaneously but the patient died a year after the diagnosis.

Comments
When injected into the vessels, Thorotrast is deposited in the reticuloendothelial system (liver, spleen, bone marrow, lymph nodes). The association with hepatic, haematologic, pulmonary and urinary malignancies has been clearly described. The mechanism by which tumours are induced involves internal irradiation with chromosomal mutations and abnormalities, but also a possible direct toxicity. Dahlgreen proposed three criteria that must be met before implicating Thorotrast as a cause of neoplasia. First, Thorotrast must be present in the vicinity of the tumour. Second, the latent
period must have been sufficiently long (average 20 years). Third, the dose must have been sufficiently high.7

As illustrated by the present case, the diagnosis of Thorotrast exposure is made upon the basis of metallic hyperdensities in the liver, spleen and lymph nodes, detected by a plain film of the abdomen which shows the pathognomonic increased density of liver, spleen and lymph nodes. Such a finding should alert the clinician to the possibility of radiation-induced malignancy. CT will confirm this, while MRI and ultrasound do not provide any further information. A liver biopsy will confirm the malignancy while the presence of Thorotrast can be confirmed by autoradiography.

The risk of developing malignancies as a result of Thorotrast exposure continues throughout the patient’s life as the radiation is continuous and linked with the long half-life of Thorotrast. In contrast, other carcinogens have usually ceased to give an increased risk at about 30 years after cessation of exposure (15 years in the case of cigarettes).

In conclusion, this case leads us to remind recently trained clinicians of this historical pathology, which obviously will disappear with time but must be kept in mind for at least two decades, when confronted with atypical abdominal pain in elderly patients.

**Learning points**

- recall of the carcinogenic role of Thorotrast
- radiologic pathognomonic patterns of Thorotrast deposits
- diagnostic interest of the plain film of the abdomen
- ‘in vivo’ confirmation of the carcinologic effects of radiation

Abdominal pain: do not forget Thorotrast!

E. Weber, F. Laarbaui, L. Michel and J. Donckier

doi: 10.1136/pgmj.71.836.367

Updated information and services can be found at:
http://pmj.bmj.com/content/71/836/367

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/